Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles
Modern Pathology · 2025-09 · 38 (9) · 100791
DOI: 10.1016/j.modpat.2025.100791 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2025-09. Verfasst von Molly L Parrish und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina; Pathobiology and T…. Hauptthemen laut MEDLINE: beta Catenin, Endometrial Neoplasms, Carcinoma, Endometrioid, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
CTNNB1 exon 3 mutation is a well-established driver of nearly 30% of endometrioid endometrial cancers (EECs), and this is associated with worse patient survival. Paradoxically, we have previously demonstrated that mutant β-catenin protein does not robustly localize to the nucleus in these cancers. The purpose of this study was to determine downstream gene expression in these cancers with nuclear or membrane/cytoplasmic mutant β-catenin protein localization. Spatial transcriptomics was performed on tumors with intratumor nuclear and nonnuclear mutant β-catenin, using the protein localization to select for regions of interest (ROIs). Differential expression analysis of all nuclear and nonnuclear ROIs yielded distinct transcriptional profiles based on the localization of β-catenin. Analysis revealed enrichment for Wnt signaling and epithelial-to-mesenchymal transition pathways in nuclear ROIs and hormone signaling in nonnuclear ROIs. Hierarchical clustering yielded 2 clusters comprised of almost entirely nuclear or nonnuclear ROIs. A novel therapeutic target, TROP2, encoded by the TACSTD2 gene, was identified to be altered by Wnt/β-catenin signaling. These data provide evidence for highly heterogeneous intratumor transcriptional profiles dependent on β-catenin protein localization in EEC with CTNNB1 driver mutations. Therefore, reporting of β-catenin immunohistochemistry should include an estimated percentage of tumor with nuclear localization in EEC tumors with exon 3 CTNNB1 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina; Pathobiology and Translational Science Graduate Program, The University of North Carolin…
- Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina.
- Department of Pathology and Laboratory Medicine, The University of North Carolina School of Medicine, Chapel Hill, North Carolina. Electronic address: agladden@email.unc.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Parrish, M. L., Osborne-Frazier, M. L., Broaddus, R. R., & Gladden, A. B. (2025). Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles. Modern Pathology, 38(9), 100791. https://doi.org/10.1016/j.modpat.2025.100791
Vancouver
Parrish ML, Osborne-Frazier ML, Broaddus RR, Gladden AB. Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles. Modern Pathology. 2025;38(9):100791. doi:10.1016/j.modpat.2025.100791
BibTeX
@article{Parrish2025,
author = {Parrish, Molly L and Osborne-Frazier, Macy L and Broaddus, Russell R and Gladden, Andrew B},
title = {Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles},
journal = {Modern Pathology},
year = {2025},
volume = {38},
number = {9},
pages = {100791},
doi = {10.1016/j.modpat.2025.100791}
}
EUVIMED